Voss D H, Cumminsky K C, Cook V D, Nethers M S, Spinnato J A, Gall S A
Department of Obstetrics and Gynecology, University of Louisville School of Medicine, KY 40292, USA.
J Matern Fetal Med. 1996 Jul-Aug;5(4):186-93. doi: 10.1002/(SICI)1520-6661(199607/08)5:4<186::AID-MFM5>3.0.CO;2-G.
To evaluate the efficacy and safety of three concentrations of prostaglandin E2 (PGE2) gel for preinduction cervical ripening. Two hundred ninety-one patients with an unfavorable cervix scheduled for induction of labor were eligible to participate in a prospective, randomized, double-blind study of one or two doses of intracervical PGE2 gel. Group 1 received a dose of 0.125 mg/2 ml; group 2 received 0.25 mg/2 ml; and group 3 received 0.5 mg/2 ml. Outcome variables included change in Bishop score, uterine tachysystole, oxytocin use, route of delivery, and maternal and neonatal complications. Two hundred twenty-nine patients were included in the study, 79 in group 1, 70 in group 2, and 80 in group 3. Among the three groups, no statistically significant differences were noted for change in Bishop score, uterine tachysystole, oxytocin use, route of delivery, or incidence of maternal or neonatal complications, Subsequent labors were frequently complicated by fetal heart rate abnormalities (24.3%) and uterine tachysystole (9.6%); 84 (38.9%) patients were delivered by cesarean section. A dose-dependent influence on outcome variables was not identified. Complications from PGE2-ripening within 4 hours of gel application were not dose dependent and occurred infrequently. This study demonstrates that there is no dose in the range tested that assures an absences of tachysystole, limiting the role of outpatient cervical ripening without some period of observation.
评估三种浓度的前列腺素E2(PGE2)凝胶用于引产术前促宫颈成熟的有效性和安全性。291例宫颈条件不佳且计划引产的患者符合参加一项关于一剂或两剂宫颈内注射PGE2凝胶的前瞻性、随机、双盲研究的条件。第1组接受一剂0.125 mg/2 ml;第2组接受0.25 mg/2 ml;第3组接受0.5 mg/2 ml。观察指标包括 Bishop 评分的变化、子宫收缩过速、催产素使用情况、分娩方式以及母婴并发症。229例患者纳入研究,第1组79例,第2组70例,第3组80例。三组之间,在 Bishop 评分变化、子宫收缩过速、催产素使用情况、分娩方式或母婴并发症发生率方面未发现统计学上的显著差异。随后的分娩经常伴有胎儿心率异常(24.3%)和子宫收缩过速(9.6%);84例(38.9%)患者通过剖宫产分娩。未发现对观察指标有剂量依赖性影响。凝胶应用后4小时内PGE2促宫颈成熟引起的并发症与剂量无关且发生率低。本研究表明,在所测试的剂量范围内,没有一种剂量能确保不出现子宫收缩过速,这限制了门诊促宫颈成熟且无观察期的作用。